Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
Chimerix, Inc. (CMRX)
Last chimerix, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.chimerix.com/investor-relations
Company Research
Source: GlobeNewswire
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chimerix and offers renewed hope for pati
Read more
Impact Snapshot
Event Time:
CMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMRX alerts
High impacting Chimerix, Inc. news events
Weekly update
A roundup of the hottest topics
CMRX
News
- Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 [Yahoo! Finance]Yahoo! Finance
- Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of ShareholdersPR Newswire
- Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of ShareholdersGlobeNewswire
CMRX
Earnings
- 3/21/25 - Beat
CMRX
Sec Filings
- 3/28/25 - Form SC
- 3/21/25 - Form SC
- 3/21/25 - Form SC
- CMRX's page on the SEC website